JP2005526520A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526520A5
JP2005526520A5 JP2004508299A JP2004508299A JP2005526520A5 JP 2005526520 A5 JP2005526520 A5 JP 2005526520A5 JP 2004508299 A JP2004508299 A JP 2004508299A JP 2004508299 A JP2004508299 A JP 2004508299A JP 2005526520 A5 JP2005526520 A5 JP 2005526520A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
pharmaceutical composition
muc
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004508299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526520A (ja
Filing date
Publication date
Priority claimed from GBGB0212046.7A external-priority patent/GB0212046D0/en
Application filed filed Critical
Publication of JP2005526520A publication Critical patent/JP2005526520A/ja
Publication of JP2005526520A5 publication Critical patent/JP2005526520A5/ja
Pending legal-status Critical Current

Links

JP2004508299A 2002-05-24 2003-05-23 Vntr反復ユニットの数が減少したmuc−1抗原 Pending JP2005526520A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines
PCT/EP2003/005594 WO2003100060A2 (en) 2002-05-24 2003-05-23 Muc-1 antigen with reduced number of vntr repeat units

Publications (2)

Publication Number Publication Date
JP2005526520A JP2005526520A (ja) 2005-09-08
JP2005526520A5 true JP2005526520A5 (enExample) 2006-06-08

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004508299A Pending JP2005526520A (ja) 2002-05-24 2003-05-23 Vntr反復ユニットの数が減少したmuc−1抗原

Country Status (20)

Country Link
US (1) US20060251665A1 (enExample)
EP (1) EP1527177A2 (enExample)
JP (1) JP2005526520A (enExample)
KR (1) KR20050004211A (enExample)
CN (1) CN100408682C (enExample)
AR (1) AR039846A1 (enExample)
AU (1) AU2003240729B2 (enExample)
BR (1) BR0311211A (enExample)
CA (1) CA2485816A1 (enExample)
GB (1) GB0212046D0 (enExample)
IL (1) IL165156A0 (enExample)
IS (1) IS7526A (enExample)
MX (1) MXPA04011527A (enExample)
NO (1) NO20044947L (enExample)
NZ (1) NZ536668A (enExample)
PL (1) PL374569A1 (enExample)
RU (1) RU2303069C2 (enExample)
TW (1) TW200407426A (enExample)
WO (1) WO2003100060A2 (enExample)
ZA (1) ZA200409445B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
ES2476990T3 (es) 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
WO2011156751A2 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
JP2014518841A (ja) * 2011-02-24 2014-08-07 オンコシレオン インク. アジュバントを備えたmuc1ベースのグリコリポペプチドワクチン
CA2954892A1 (en) * 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
AU2017336269B2 (en) * 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101028523A (zh) * 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物
CA2282300C (en) * 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
US20020142047A1 (en) * 2001-01-19 2002-10-03 Johnson Mark E. Microsphere delivery of mucin peptides
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Similar Documents

Publication Publication Date Title
US10973909B1 (en) Coronavirus vaccine
JP5873335B2 (ja) フィブロネクチンiii型ドメインに基づくスカフォールド組成物、方法及び使用
JP5848607B2 (ja) フィブロネクチン3型ドメインに基づくスカフォールド組成物、方法及び使用
JP2009292810A5 (enExample)
RU2016109939A (ru) Способ повышения экспрессии кодируемых рнк белков
CA2529179A1 (en) Recombinant adeno-associated virus vector for treatment of alzheimer disease
JP2006020648A5 (enExample)
JP2008056679A5 (enExample)
JP2015501840A5 (enExample)
JP2009515831A5 (enExample)
DE60014076D1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
JP2005538932A5 (enExample)
JP2016513115A5 (enExample)
JP2008507536A5 (enExample)
JP2008535800A5 (enExample)
AU2008302035A1 (en) Nanotherapeutic colloidal metal compositions and methods
JP2002542827A5 (enExample)
JP2005102701A5 (enExample)
JP2011517938A5 (enExample)
JP2003530088A5 (enExample)
RU2004134331A (ru) Антиген muc1 со сниженным числом повторяющихся vntr-блоков
JP2019531293A5 (enExample)
JP2006506942A5 (enExample)
JP2004531242A5 (enExample)
JP2016501528A5 (enExample)